Dr. Garmezy on impact of antibody-drug conjugates on bladder cancer treatment paradigm
“What’s really exciting over the next few years is how are these antibody-drug conjugates that are already FDA-approved going to partner with other current drugs that we can use to treat this disease, such as immunotherapy,” says Garmezy.
Benjamin Garmezy, MD, discusses the FDA-approved antibody-drug conjugates (ADCs) enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy) and the next steps with ADCs in the treatment paradigm for patients with urothelial carcinoma.
Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
FDA accepts resubmission of BLA for N-803 in NMIBC
October 26th 2023The FDA has accepted a resubmitted biologics license application for N-803 for use in combination with BCG for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
